Justin Gregg, MD, on the Use of the Mediterranean Diet in Men With Localized Prostate Cancer

The assistant professor of Urology at The University of Texas MD Anderson Cancer Center spoke about the results of a study which evaluated the use of the Mediterranean diet in men with localized prostate cancer on active surveillance.

The Mediterranean diet was revealed to be associated with a lower risk of Gleason Grade group progression among men with localized prostate cancer on active surveillance, according to a study (NCT00490763) published in Cancer.

These findings are consistent with previous reports of the Mediterranean diet, resulting in reductions in cancer morbidity and mortality. However, follow-up in larger studies of men enrolled on active surveillance are still necessary to verify patient- and cancer-specific effects of adherence to the Mediterranean diet in men with early-stage prostate cancer.

In an interview with CancerNetwork®, Justin Gregg, MD, assistant professor of Urology at The University of Texas MD Anderson Cancer Center as well as lead author of the study, discussed these findings and what led he and his colleagues to conduct this research.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences channels.

Reference:

Gregg JR, Zhang X, Chapin BF, et al. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort. Cancer. Published online January 7, 2020. doi:10.1002/cncr.33182

Related Videos
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Expert cardiologist
Expert urologist
Expert cardiologist
Expert urologist
Expert urologist
Related Content